Scientists discover role for Cdk4 in making cells cancer resistant

November 14, 2002

A report published in the November 15th issue of Genes & Development details a requirement for cyclin dependent kinase 4 (Cdk4) gene expression in Ras-induced oncogenesis -- highlighting Cdk4 suppression as a potential therapeutic tool to combat the ~30% of human tumors in which the Ras oncogene is activated.

Cancer results from the acquisition of mutations in genes that function as oncogenes (the encoded protein promotes cell growth) or tumor suppressors (the encoded protein regulates the cell growth cycle), leading to their aberrant activation or repression, respectively. Although individual cancer cells have a unique etiology, or blueprint of genetic mutations that confer upon them the ability for unregulated cell proliferation, researchers have identified a few usual suspects: genes that are mutated in a large number of human cancers. For example, the Ras oncogene is activated in roughly one third of all human tumors, while the p53 tumor suppressor gene is inactivated in half.

Dr. Hiroaki Kiyokawa and colleagues have found that expression of a gene called Cdk4 is essential for Ras-induced cancer development, regardless of p53 status or the presence of another frequently mutated tumor suppressor gene, Ink4a/Arf.

The Cdk4 protein promotes progression through the G1 (initial) phase of the cell growth cycle. Accumulating evidence has implicated aberrant Cdk4 activation in the development of a variety of human tumors, including breast cancer, glioblastomas, sarcomas, and melanomas. Thus, Dr. Kiyokawa and colleagues generated mouse cells deficient in Cdk4 in order to determine its role in tumorigenesis.

Dr. Kiyokawa and colleagues deleted the Cdk4 gene in mouse embryonic fibroblast cells (MEFs; connective tissue cells derived from mouse embryos) in a variety of different genetic backgrounds, and assayed these cells for tumorigenicity both in cell culture (via their ability to divide indefinitely, or act "immortal") and in live mice (via their ability to form solid tumors when injected into immunocompromised mice). The researchers found that while Cdk4-deficient cells grow and divide normally under standard conditions, once the Ras oncogene is activated, these cells retreat into a cancer-resistant state of terminal growth arrest, called senescence. Ras-expressing Cdk4-deficient cells also senescence when either the p53 or Ink4a/Arf tumor suppressor gene is inactivated, demonstrating that Cdk4 is required for tumorigenesis even when commonly mutated tumor suppressor genes are non-functional.

This discovery that diminished Cdk4 expression steers cells into a protective state of senescence against oncogenes like Ras has significant therapeutic implications. In light of the frequency with which the Ras oncogene is expressed and the p53 or Ink4a/Arf tumor suppressor pathway is disabled in human tumors, the deliberate suppression of Cdk4 activity may provide an alternate point of entry for doctors to regulate the cell growth cycle and halt tumorigenesis.
-end-


Cold Spring Harbor Laboratory

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.